Dr Reddy's announces commercial launch of DRDO's anti-COVID-19 drug 2DG
By MYBRANDBOOK
Hyderabad-based Dr Reddy’s Laboratory announced the commercial launch of the anti-Covid-19 drug, 2-Deoxy-D-Glucose (2-DG) for hospitalized moderate to severe Covid-19 patients.
The anti-Covid therapeutic application of 2-DG has been jointly developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), Defence Research and Development Organisation (DRDO), and Dr Reddy’s Laboratories.
The drug will be supplied to both Government and private Covid-19 health facilities across India. “ The drugs initially will be available at hospitals across metros and Tier 1 cities and in later course expand coverage to rest of the nation, said a company statement and the maximum selling price has been capped at ₹990, with a discounted rate offered to government institutions, it said.
The government institutions will receive at a subsidized rate. Satish Reddy, Chairman, Dr. Reddy’s in the official statement said that 2-DG is another addition to the company’s existing COVID-19 treatment portfolio for mild to moderate and severe conditions and includes a vaccine.
Dr Reddy’s has signed an agreement to distribute Russia’s Covid-19 vaccine Sputnik V in partnership with Snowman Logistics. The Defense Minister, Rajnath Singh had earlier announced that he would personally honour the scientists who played a critical role in the development of the drug as they deserve credit for this achievement.
As per the sources, 2-DG, made of the generic molecule along with an analogue of glucose, accumulates in the virus-infected cells of the body and prevents the invasion of the virus from one cell to another. Viral synthesis and energy production of the virus is cut short stopping it to grow faster helping Covid patients to no longer depend on supplemental oxygen and recover faster.
Initial trials for the drug were conducted between May and October last year at 110 patients at six hospitals. The final phase of the clinical trials was concluded in March 2021 on 220 patients at 27 Covid hospitals. The data from the 2-DG trials suggested the drug usage was safe and Covid-19 patients showed significant recovery.
Nazara and ONDC set to transform in-game monetization with ‘
Nazara Technologies has teamed up with the Open Network for Digital Comme...
Jio Platforms and NICSI to offer cloud services to government
In a collaborative initiative, the National Informatics Centre Services In...
BSNL awards ₹5,000 Cr Project to RVNL-Led Consortium
A syndicate led by Rail Vikas Nigam Limited (abbreviated as RVNL), along wi...
Pinterest tracks users without consent, alleges complaint
A recent complaint alleges that Pinterest, the popular image-sharing platf...
MATRIX COMSEC PVT. LTD.
CENTRE FOR DEVELOPMENT OF TELEMATICS (C-DOT)
DATA SAFEGUARD INDIA PRIVATE LIMITED
NETWEB TECHNOLOGIES INDIA LTD.
ICONS OF INDIA : SANTHOSH VISWANATHAN
Santhosh Viswanathan is the the Vice President and Managing Director f...
ICONS OF INDIA : RAJESH NAMBIAR
Rajesh leads the company’s India associates and enhances relationshi...
Icons Of India : AALOK KUMAR
Aalok Kumar is celebrated as a global leader and recipient of the Peop...
BEL - Bharat Electronics Limited
BEL is an Indian Government-owned aerospace and defence electronics co...
CERT-IN - Indian Computer Emergency Response Team
CERT-In is a national nodal agency for responding to computer security...
UIDAI - Unique Identification Authority of India
UIDAI and the Aadhaar system represent a significant milestone in Indi...
Indian Tech Talent Excelling The Tech World - NEAL MOHAN, CEO - Youtube
Neal Mohan, the CEO of YouTube, has a bold vision for the platform’s...
Indian Tech Talent Excelling The Tech World - JAY CHAUDHRY, CEO – Zscaler
Jay Chaudhry, an Indian-American technology entrepreneur, is the CEO a...
Indian Tech Talent Excelling The Tech World - Rajiv Ramaswami, President & CEO, Nutanix Technologies
Rajiv Ramaswami, President and CEO of Nutanix, brings over 30 years of...